Quantitative analysis of a novel HIV fusion inhibitor (sifuvirtide) in HIV infected human plasma using high-performance liquid chromatography–electrospray ionization tandem mass spectrometry
Authors:
- 1 March 2010
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 51 (4) , 927-933
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion InhibitorJournal of Biological Chemistry, 2008
- Historical review of sample preparation for chromatographic bioanalysis: pros and consDrug Development Research, 2007
- Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAARTPLOS Medicine, 2006
- Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2006
- An Improved HPLC Fluorimetric Method for the Determination of Enfuvirtide Plasma Levels in HIV-Infected PatientsTherapeutic Drug Monitoring, 2006
- Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC–MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2005
- Quantification of sifuvirtide in monkey plasma by an on‐line solid‐phase extraction procedure combined with liquid chromatography/electrospray ionization tandem mass spectrometryRapid Communications in Mass Spectrometry, 2005
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998